Bashiru Ibrahim | Cancer Cells | Best Researcher Award

Published on by Oncology

Dr. Bashiru Ibrahim | Cancer Cells | Best Researcher Award

Research Fellow | University of Birmingham | United Kingdom

Dr. Bashiru Ibrahim is a highly skilled nanotoxicology and environmental science researcher with a strong academic foundation and extensive laboratory, teaching, and project management experience. He holds a PhD in Nanotoxicology from the University of Birmingham, where his research focused on the toxicological effects of metallic nanomaterials on lung epithelial cells, examining their interactions with cellular stress pathways, protein degradation systems, and intracellular uptake mechanisms. His academic journey also includes an MSc in Environmental Science with Distinction from the Islamic University in Uganda, where he studied the relationship between waterborne diseases and community water-handling practices, and a BSc in Biochemistry from Usmanu Danfodiyo University in Nigeria. Ibrahim has developed advanced expertise in nanomaterial synthesis, characterisation, cytotoxicity assays, flow cytometry, ICP-MS, confocal microscopy, and data analysis using multiple statistical software tools. He has worked as a Research Associate at the University of Birmingham, contributing to major international projects such as ACCORDs and NanoSolveIT, where he synthesised and characterised diverse nanomaterials, performed toxicological assessments using various cell lines and zebrafish models, and supported sustainable material design initiatives.

Citation Metrics (Google Scholar)

260

240

200

160

120

80

40

 

Citations
222
i10 Index
8
h-Index
9
        🟦 Citations          🟥I- 10 Index      🟩 h-index

View Google Scholar Profile

Featured Publications

Harini Keerthana SureshKumar | Cancer Cells | Best Researcher Award

Published on by Oncology

Ms. Harini Keerthana SureshKumar | Cancer Cells | Best Researcher Award 

PhD | Universitätsklinikum Heidelberg | Germany

Ms. Harini Keerthana SureshKumar is a dedicated biomedical scientist and emerging oncology researcher whose strong academic foundation and diverse research experience make her highly suitable for a Best Researcher Award. Currently pursuing her PhD in Anaesthesiology at Universitätsklinikum Heidelberg, she focuses on intraoperative cell salvage in oncological surgery while building on a solid background in molecular medicine and biomedical sciences. Her research journey includes extensive work in cell signaling, infection biology, microbial genomics, and cancer-related translational studies, supported by hands-on expertise in advanced laboratory techniques such as flow cytometry, immunoblotting, plasmid transfection, siRNA methodologies, viral assays, histology, microscopy, microbial culturing, genome analysis, and molecular diagnostics. She has contributed to impactful scientific literature, publishing in reputed journals including the European Journal of Surgical Oncology, Cell Communication and Signaling, Annals of Microbiology, Cells, and the Journal of Microbiology, Biotechnology and Food Sciences, along with depositing microbial genome sequences in the NCBI database. Ms. Harini has demonstrated research excellence through multiple roles as a research assistant and intern across prestigious German and Indian institutions, consistently applying complex methodologies to clinically relevant projects. Her academic achievements are complemented by recognition such as the Highly Recommended Poster Award at NATA’s 25th Anniversary Congress and winning the MIT COVID-19 Challenge in India. She has further strengthened her research competencies by completing specialized courses in microscopy, transgenic models, molecular intensive care, scientific ethics, and animal research regulations. Actively engaged in international conferences and scientific workshops, she reflects a strong commitment to innovation, collaboration, and scientific advancement. Alongside her technical abilities, she brings organizational strengths, problem-solving skills, and strong interpersonal capabilities, making her a promising young scientist with clear potential for significant future contributions to oncology and biomedical research.

Profile: ORCID

Featured Publications

  1. SureshKumar, H., Schenz, J., Waters, J. H., Weigand, M. A., Seyfried, T., Juratli, M. A., Frietsch, T., & Fischer, D. (2025). Revisiting the safety of intraoperative cell salvage in cancer surgery: How to evaluate the functional properties of remaining cancer cells. European Journal of Surgical Oncology. DOI: 10.1016/j.ejso.2025.110532

  2. Hornung, F., SureshKumar, H. K., Klement, L., Reisser, Y., Wernike, C., Nischang, V., Jordan, P. M., Werz, O., Hoffmann, C., Löffler, B., et al. (2025). High-fat diet impairs microbial metabolite production and aggravates influenza A infection. Cell Communication and Signaling. DOI: 10.1186/s12964-025-02367-w

  3. Hussain, I., Sureshkumar, H. K., Bauer, M., & Rubio, I. (2023). Starvation protects hepatocytes from inflammatory damage through paradoxical mTORC1 signaling. Cells, 12(12), 1668. DOI: 10.3390/cells12121668

  4. Suresh Kumar, H. K., Gopikrishna, T., Tapasya, K., Perumal, K., & Elavarashi, E. (2023). A computational genome analysis of strain Bacillus subtilis MIZ-8 isolated from Bekang reveals a distinct chromosome and plasmid conferring selective advantage. Journal of Microbiology, Biotechnology and Food Sciences, 13(2), e9141. DOI: 10.55251/jmbfs.9141

  5. Gopikrishna, T., Suresh Kumar, H. K., Perumal, K., & Elangovan, E. (2021). Impact of Bacillus in fermented soybean foods on human health. Annals of Microbiology, 71, 30. DOI: 10.1186/s13213-021-01641-9

Ms. Harini Keerthana SureshKumar’s research advances the safety and precision of cancer surgery while deepening scientific understanding of immune responses, microbial interactions, and cellular signaling. Her contributions support improved clinical outcomes, inform translational innovations, and strengthen global efforts in oncology, infectious disease biology, and patient-centered healthcare.

Jaweher Bday | Cancer Research | Best Researcher Award

Published on by Oncology

Ms. Jaweher Bday | Cancer Research | Best Researcher Award 

PhD Student | Higher Institute of Biotechnology of Monastir | Tunisia

Ms. Jaweher Bday is a highly promising PhD researcher in biotechnology with a robust specialization in immuno-oncology, demonstrating strong potential and clear suitability for a Best Researcher Award through her scientific rigor, technical depth, and impactful research outputs. Her academic journey—from a bachelor’s degree in molecular and cellular biology, a research master’s in cell biology and physiology, to an ongoing PhD at the Higher Institute of Biotechnology of Monastir—illustrates continuous progression and dedication to cancer research. She has completed several competitive international research internships in leading laboratories in France, including the Bio PeroxIL Laboratory at the University of Burgundy and the INSERM U1307 Laboratory at the University of Nantes, enhancing her expertise in cell death mechanisms, tumor biology, and advanced molecular techniques. Her publication record is strong and growing, with peer-reviewed articles in recognized journals on topics such as arginase regulation in HPV infection, hybrid cell-death induction in breast cancer models, and the role of nitric oxide pathways in cervical carcinogenesis, along with an additional submitted manuscript on HPV circulating markers. Jaweher’s scientific maturity is evidenced by her active participation in conferences, including oral and poster presentations at national and international oncology and toxicology meetings, reflecting substantial dissemination of her research. Beyond laboratory excellence, she demonstrates leadership through major roles in the Tunisian Association of Biotechnology Students, including serving as President and spearheading scientific events and innovation-focused programs. Her teaching activities, spanning workshops, directed courses, and hands-on training, further showcase her commitment to academic development and knowledge transfer. Equipped with advanced laboratory skills, strong analytical proficiency using tools like FlowJo, ImageJ, SPSS, and GraphPad, along with extensive training in scientific writing, publishing, quality management, and pedagogy, she embodies the qualities of an emerging researcher with both scientific impact and community engagement. Overall, her achievements, productivity, international exposure, and leadership make her an excellent candidate for a Best Researcher Award.

Profile: ORCID

Featured Publications

  1. Souid, M., Bday, J., Souissi, S., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Toumi, D., Bergaoui, H., Zouari, I., Faleh, R., Zakhama, A., & Hassen, E. (2023). Arginase is upregulated in healthy women infected by oncogenic HPV types. Biomarkers, 28(7), 628–636.

  2. Bday, J., Souid, M., Pires, V., Gabbouj, S., Véjux, A., Lizard, G., & Hassen, E. (2025). Arginase activity inhibition with thymoquinone induces a hybrid type of cell death in MDA-MB-231 cell line. Journal of Biochemical and Molecular Toxicology, 39(2), e70130.

  3. Bday, J., Souid, M., Farhat, K. H., Macherki, Y., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Faleh, R., & Hassen, E. (2025). Involvement of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) levels in precancerous and cancerous cervical lesions. Nitric Oxide, 159, 176–185.

  4. Souid, M., Ghedira, R., Bday, J., Gabbouj, S., Shini-Hadhri, S., Hajji, A., Faleh, R., & Hassen, E. (Under review). Human Papillomavirus-16 circulating markers distribution among unvaccinated women. Infectious Diseases Now.

  5. Bday, J., Souid, M., Pires, V., Véjux, A., Lizard, G., & Hassen, E. (2025). Hybrid cell-death mechanisms in breast cancer: Insights from thymoquinone-mediated arginase inhibition. Manuscript in preparation.

Ms. Jaweher Bday’s work advances immuno-oncology by uncovering novel cellular and molecular mechanisms that can drive more precise cancer diagnostics and targeted therapies. Her research contributes to global health by improving understanding of HPV-related cancers and breast cancer biology, supporting innovations that can shape future clinical and translational applications. Through scientific leadership, teaching, and community engagement, she helps strengthen research capacity and fosters the next generation of biotechnology innovators.

Aminah Alotaibi | Breast Cancer | Best Researcher Award

Published on by Oncology

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Rui Liu | Tumor Radiobiology | Best Researcher Award

Published on by Oncology

Dr. Rui Liu | Tumor Radiobiology | Best Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

SCOPUS ID

GOOGLE SCHOLAR

🏥DR. RUI LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Rui Liu began her academic journey with a strong foundation in biomedical sciences, eventually earning a Ph.D. from a prestigious institution renowned for excellence in public health and molecular oncology. Her early research experiences centered on cellular biology and radiation mechanisms, which laid the groundwork for her specialization in tumor radiobiology and DNA damage repair (DDR).

🩺PROFESSIONAL ENDEAVORS

Currently serving as a Lecturer at the School of Public Health, Wenzhou Medical University, Dr. Liu has dedicated herself to cutting-edge cancer research. With over five years of hands-on laboratory experience, she has developed deep expertise in molecular biology, gene editing (CRISPR-Cas9), animal modeling, bioinformatics, and cellular imaging technologies. Her academic career reflects a balance between rigorous research and impactful teaching, mentoring the next generation of oncology researchers.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR RADIOBIOLOGY

Dr. Liu’s core research explores the molecular intricacies of radiotherapy resistance, with a focus on DNA damage repair pathways and ferroptosis in tumor cells. She has pioneered studies that unravel how long non-coding RNAs (lncRNAs) like MALAT1 influence cancer cell radiosensitivity, potentially leading to enhanced radiotherapy strategies. Her work contributes valuable insights into overcoming therapeutic resistance in breast cancer and other solid tumors.

🌍IMPACT AND INFLUENCE

Dr. Liu’s research has significantly advanced understanding in her field, evidenced by 445+ citations, an H-index of 12, and impactful publications in SCI-indexed journals. She is an active voice in the scientific community, engaging in collaborative research with Jilin University and contributing to national and provincial projects. Her affiliations with professional societies amplify her influence in radiological toxicology and environmental biophysics.

🏆 ACCOLADES AND RECOGNITION

Notable Awards:

  • 🎓 National Scholarship for Doctoral Excellence

  • 🌟 Recognition as a promising young investigator in radiobiology

🏆LEGACY AND FUTURE CONTRIBUTIONS

As an emerging leader in radiation oncology research, Dr. Liu aims to translate molecular findings into clinical applications that improve therapeutic outcomes. She mentors student researchers and continues to expand her interdisciplinary work on novel radiotherapy biomarkers, synthetic lethality, and non-coding RNA therapeutics. Her commitment ensures sustained contributions to precision oncology and translational cancer science.

🧬CONCLUSION

Dr. Rui Liu exemplifies the next generation of scientists transforming cancer treatment through molecular radiobiology. With a robust publication record, interdisciplinary collaborations, and active academic service, she is poised to leave a lasting impact on oncology research, education, and clinical innovation. Her ongoing efforts promise to redefine therapeutic strategies for radiation-resistant cancers.

📊🔬NOTABLE PUBLICATION:

Title: Metal ions overloading and cell death
Authors: Y. Lai, F. Gao, R. Ge, R. Liu, S. Ma, X. Liu
Journal: Cell Biology and Toxicology
Year: 2024

Title: Post‐translational modifications of protein in response to ionizing radiation
Authors: X. Liu, R. Liu, Y. Bai, H. Jiang, X. Fu, S. Ma
Journal: Cell Biochemistry and Function
Year: 2020

Title: The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China
Authors: F. Shi, H. Wen, R. Liu, J. Bai, F. Wang, S. Mubarik, X. Liu, Y. Yu, Q. Hong, J. Cao, …
Journal: Global Health Research and Policy
Year: 2021

Title: Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population
Authors: R. Liu, L. Ning, X. Liu, H. Zhang, Y. Yu, S. Zhang, W. Rao, J. Shi, H. Sun, Q. Yu
Journal: Oncotarget
Year: 2017

Title: The challenges of precision radiotherapy technology to the traditional theory of radiobiology
Authors: S. Ma, Z. Liang, Q. Chen, R. Liu, Y. Guo, X. Liu
Journal: Chinese Journal of Radiological Medicine and Protection
Year: 2019

Title: Tumor-associated macrophages in radiotherapy: Mechanisms of polarization, immune regulation and therapeutic strategies
Authors: S. Ma, Z. Liang, X. Liu, R. Liu
Journal: Frontiers in Oncology
Year: 2023

Ping Dai | Cancer Therapy | Best Researcher Award

Published on by Oncology

Dr. Ping Dai | Cancer Therapy | Best Researcher Award

Tongji University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.

🩺PROFESSIONAL ENDEAVORS

With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS  IN CANCER THERAPY

Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.

🌍IMPACT AND INFLUENCE

Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.

  • Honored with Outstanding Master’s Graduate award.

  • Latin honors “Magna Cum Laude” for doctoral studies in Germany.

  • Recognized as equal-first author and corresponding author in multiple prestigious publications.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:

  • Advance predictive markers for immunotherapy outcomes.

  • Explore MSC-based interventions against radiation-induced myelotoxicity.

  • Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.

🧬CONCLUSION

Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.

📊🔬NOTABLE PUBLICATION:

Thyroid dysfunction as a predictor of PD-1/PD-L1 inhibitor efficacy in advanced lung cancer

Authors: Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
Journal: BMC Cancer
Year: 2025

Comprehensive Simulations of Intracellular Electric Fields during Exposure to Tumor Treating Fields (TTFields)

Authors: Kaida Liu, Ping Dai, Zirong Liu, Haohan Fang, Xing Li, Wei Gao
Journal: Frontiers in Oncology
Year: 2025 (Accepted)

Electrodynamic Interaction between Tumor Treating Fields and Microtubule Electrophysiological Activities

Authors: Xing Li, Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai
Journal: APL Bioengineering
Year: 2024

A theoretical study on evaluating brain tumor changes in tumor treating fields therapy by impedance detection

Authors: Xing Li, Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai
Journal: Frontiers in Oncology
Year: 2024

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Published on by Oncology

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Yueyang Central Hospital | China

AUTHOR PROFILE

ORCID ID

📚EARLY ACADEMIC PURSUITS 

ZENG QINGJUN completed his Master’s degree at Xiangya Medical College, Central South University, in 2010. This prestigious institution provided a strong foundation in medical education, equipping him with the skills and knowledge necessary for his future in the field of gastrointestinal surgery. His academic training allowed him to develop expertise in complex surgical techniques, laying the groundwork for his career as a clinical specialist in surgery.

⚕️PROFESSIONAL ENDEAVORS 

Since July 2010, ZENG QINGJUN has been working in the field of gastrointestinal surgery, focusing on laparoscopic techniques for treating gastric and colorectal cancers. As a chief physician, he plays a pivotal role in leading surgical teams, performing high-risk surgeries, and making critical decisions for patient care. His clinical expertise and skillful handling of over 200 laparoscopic gastric cancer surgeries and 400 laparoscopic colorectal cancer surgeries are testaments to his proficiency in minimally invasive surgical methods. His surgical outcomes have contributed significantly to improving the quality of life for cancer patients and are recognized within the medical community.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON GASTROINTESTINAL TUMORS

Dr. ZENG has dedicated much of his professional life to the development and refinement of laparoscopic surgical techniques in the treatment of gastrointestinal cancers. His research is heavily focused on advancing minimally invasive surgery, particularly in the areas of gastric cancer and colorectal cancer. Through clinical trials and innovative methodologies, he has been involved in optimizing surgical procedures to ensure better postoperative recovery, reduced complications, and more efficient treatment pathways for cancer patients.

🌍IMPACT AND INFLUENCE 

Dr. ZENG QINGJUN has made an immense impact on the practice of gastrointestinal surgery in China, particularly in the realm of laparoscopic surgery. His innovative approaches and commitment to cutting-edge techniques have influenced both local and national surgical practices. His contribution to gastric and colorectal cancer surgery has improved patient outcomes and has set new standards in the field. As a chief physician, he mentors younger surgeons and shares his expertise, ensuring the continued progress of surgical techniques.

📑ACADEMIC CITATIONS 

While detailed citation metrics are not provided, Dr. ZENG’s extensive clinical experience and research endeavors have led to his recognition in academic circles. His focus on laparoscopic techniques and cancer surgery continues to influence current and future generations of surgeons and researchers in the field. His work, particularly in gastric and colorectal cancer, has made notable contributions to medical literature and has been referenced in various academic and clinical studies.

🌱LEGACY AND FUTURE CONTRIBUTIONS 

Dr. ZENG QINGJUN’s career reflects a legacy of excellence in surgical practice and medical innovation. His pioneering work in laparoscopic surgery and cancer treatment has already set the stage for future breakthroughs in the field of gastrointestinal oncology. Looking forward, he is likely to contribute even more significantly to surgical research, possibly expanding his focus to robot-assisted surgeries, postoperative care advancements, and the integration of AI in surgical planning. His mentorship, both locally and nationally, will shape the future of surgical education and the next generation of gastrointestinal surgeons.

💼LEADERSHIP IN SURGICAL PRACTICE 

Dr. ZENG continues to hold a significant leadership role in the surgical department at his medical institution. His capacity as chief physician enables him to make high-level decisions in clinical practice, direct surgical teams, and implement best practice guidelines. His strategic leadership in gastrointestinal surgery helps to establish protocols for laparoscopic surgeries, improving surgical outcomes, and pushing the boundaries of traditional approaches.

🔗 CONCLUSION

Dr. Zeng Qingjun is a distinguished gastrointestinal surgeon whose work has significantly advanced the field of laparoscopic surgery for gastric and colorectal cancers. With over a decade of experience and hundreds of successful surgeries, his contributions have set new standards in minimally invasive surgical techniques, improving patient outcomes and recovery times. Through his leadership as chief physician, he has not only influenced clinical practices but has also become a mentor to aspiring surgeons, ensuring the continuity of high-quality surgical education.

📊🔬NOTABLE PUBLICATION:
  • 1. Title: Knockdown of BUB1B Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer by Regulating the JNK/c-Jun Signaling Pathway
    Authors: Qingjun Zeng, Sanjun Zhang, Linfang He, Qingyan Fu, Li Liao, Linjie Chen, Xiang Ding
    Journal: Cancer Biotherapy and Radiopharmaceuticals
    Year: 2023

    2. Title: Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells
    Authors: Xiang Ding, Qingyan Fu, Weixing Chen, Linjie Chen, Qingjun Zeng, Sanjun Zhang, Linfang He
    Journal: Cell Biology International
    Year: 2022

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Published on by Oncology

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Kansai Medical University Hospital | Japan

AUTHOR PROFILE

Scopus

ORCID Id

🧑‍🎓 EARLY ACADEMIC PURSUITS 📚

Dr. Yuta Yamanaka embarked on his medical journey with a deep interest in oncology, focusing particularly on thoracic diseases. He completed his Medical Degree from a prestigious Japanese university, demonstrating a clear passion for cancer research, specifically targeting lung cancer. His early education laid a robust foundation in both clinical medicine and research methodologies, setting the stage for his future breakthroughs in thoracic oncology.

🩺 PROFESSIONAL ENDEAVORS 🏥

Dr. Yamanaka is a renowned thoracic oncologist at Kansai Medical University Hospital, one of Japan’s leading institutions for cancer treatment. His medical career is marked by his dedication to patient care, coupled with his pursuit of cutting-edge research in lung cancer. As a departmental leader, Dr. Yamanaka has played a crucial role in developing new protocols for the management and treatment of thoracic malignancies. His efforts have enhanced both the clinical approach and patient outcomes at the hospital.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LUNG CANCER🔍

Dr. Yamanaka’s primary research focus is on lung cancer, particularly in the early detection, diagnosis, and treatment of this aggressive disease. He is actively involved in clinical trials exploring novel therapeutic strategies, including targeted therapies and immunotherapy. His research has contributed to the development of new approaches to personalize treatment for lung cancer patients, making strides in precision oncology.

Additionally, Dr. Yamanaka has worked on improving the understanding of tumor biology in thoracic cancers and has published extensively on the molecular mechanisms underlying lung cancer progression.

🌍 IMPACT AND INFLUENCE 💡

Dr. Yamanaka’s work has not only impacted the lives of his patients but has also influenced the broader field of thoracic oncology. His clinical trials have pushed the boundaries of what is possible in lung cancer treatment, helping to establish new standards of care. Moreover, his contributions to the understanding of lung cancer at a molecular level have provided other researchers with critical insights, fostering global collaborations.

🏆 ACADEMIC CITES AND RECOGNITION 📜

Dr. Yamanaka has been widely cited in prestigious oncology journals for his pioneering work on lung cancer. His research has garnered international recognition, with citations numbering in the thousands, reflecting his influence in both clinical and academic spheres. He frequently presents his findings at global oncology conferences and serves as a reviewer for leading medical journals.

🔮 LEGACY AND FUTURE CONTRIBUTIONS 🌟

Looking forward, Dr. Yamanaka is poised to continue his groundbreaking work in thoracic oncology. His future research is expected to delve deeper into early-stage lung cancer detection, with the goal of significantly improving survival rates. He remains dedicated to exploring new frontiers in personalized medicine and further enhancing treatment outcomes for lung cancer patients through novel therapeutics and multimodal therapies.

Dr. Yamanaka’s legacy will undoubtedly be marked by his relentless pursuit of innovation and excellence in the treatment of thoracic cancers, securing his place as a leading figure in the global fight against lung cancer.

Dr. Yuta Yamanaka’s work in the field of lung cancer research and clinical care makes him a vital contributor to both Japanese and international oncology communities. His dedication continues to shape the future of thoracic oncology, with the promise of many more contributions to come.

✨ CONCLUSION 🎯

Dr. Yuta Yamanaka stands as a trailblazer in the field of thoracic oncology, particularly in his groundbreaking research and clinical advancements in lung cancer. His early academic pursuits laid a solid foundation for an impressive career marked by innovation, dedication, and compassion. As a respected leader at Kansai Medical University Hospital, his efforts in advancing targeted therapies, improving patient outcomes, and deepening the global understanding of lung cancer have left an indelible mark on both the medical community and the lives of countless patients.

 

📊🔬NOTABLE PUBLICATION:

 

    • Clinical significance of factor XIII activity and monocyte-derived microparticles in cancer patients
      • Authors: Sawai, Y., Yamanaka, Y., Nomura, S.
      • Journal: Vascular Health and Risk Management
      • Year: 2020

     

    • Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study
      • Authors: Takeda, T., Yamada, T., Kunimatsu, Y., Kurata, T., Takayama, K.
      • Journal: Cancers
      • Year: 2023

     

    • Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older
      • Authors: Yagishita, S., Yamanaka, Y., Kurata, T., Mizugaki, H., Hamada, A.
      • Journal: Clinical Pharmacology and Therapeutics
      • Year: 2024

     

    • Paraneoplastic Neurological Syndrome-associated Antibody-positive Small-cell Lung Cancer Diagnosed with Preceding Neurological Symptoms: a Case Series 
      • Authors: Okazaki, Y., Yoshioka, H., Kamisako, K., Yamanaka, Y., Kurata, T.
      • Journal: Japanese Journal of Lung Cancer
      • Year: 2024

     

    • Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer
      • Authors: Katsushima, U., Hase, K., Fukushima, T., Imai, Y., Kurata, T.
      • Journal: Japanese Journal of Clinical Oncology
      • Year: 2024

Assoc Prof Dr. Elcin Aydin | Endometrium Cancer | Best Researcher Award

Published on by Oncology

Assoc Prof Dr. Elcin Aydin | Endometrium Cancer | Best Researcher Award

University of Health Sciences, Izmir | Turkey

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

  • Assoc Prof Dr. Elçin Aydın’s academic journey began with a strong foundation in medical sciences. She pursued her education with a focus on radiology, demonstrating a keen interest in the diagnostic and therapeutic applications of imaging technologies. Her early academic pursuits laid the groundwork for her specialization in abdominal and genitourinary radiology.

PROFESSIONAL ENDEAVORS

  • Dr. Aydın is currently affiliated with the University of Health Sciences in Izmir, Turkey, and works at Izmir City Hospital. Her professional endeavors have been marked by a commitment to clinical excellence and academic rigor. She has been an active member of prestigious organizations such as the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), the European Congress of Radiology (ECR), and the European Society of Urogenital Radiology (ESUR).

CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Aydın has made significant contributions to the field of radiology through her research and clinical work. She has published 14 original articles in SCI-EXP indexed journals and authored 4 case studies, highlighting her expertise in abdominal and genitourinary radiology. Her research focuses on the diagnostic accuracy and clinical applications of imaging techniques in these areas, aiming to improve patient outcomes through advanced radiological practices.

IMPACT AND INFLUENCE

  • Through her scholarly publications and clinical practice, Dr. Aydın has had a considerable impact on the field of radiology. Her work is frequently cited by peers, reflecting the influence of her research on contemporary radiological practices. Her involvement in ESGAR, ECR, and ESUR underscores her influence within the radiological community, where she contributes to the advancement of knowledge and practice standards.

ACADEMIC CITATIONS

  • Dr. Aydın’s research has garnered significant academic attention, with numerous citations in prominent radiological journals. Her studies on abdominal and genitourinary radiology are referenced by other researchers and clinicians, indicating the high regard in which her work is held. This academic recognition is a testament to the quality and relevance of her research contributions.

LEGACY AND FUTURE CONTRIBUTIONS ON ENDOMETRIUM CANCER

  • Dr. Aydın’s legacy in the field of radiology is characterized by her dedication to advancing medical imaging and improving patient care. Looking ahead, she is poised to continue her impactful research and clinical work, with a focus on innovative imaging techniques and their applications in abdominal and genitourinary radiology. Her future contributions are expected to further enhance the understanding and practice of radiology, benefiting both the medical community and patients.

OTHER IMPORTANT TOPICS

TEACHING AND MENTORSHIP

  • In addition to her research and clinical responsibilities, Dr. Aydın is deeply committed to teaching and mentoring the next generation of radiologists. Her role at the University of Health Sciences allows her to shape the education and training of medical students and residents, ensuring the continued growth and development of the field.

COLLABORATIVE PROJECTS

  • Dr. Aydın actively engages in collaborative projects with other institutions and researchers. These collaborations enable the sharing of knowledge and expertise, fostering innovation and improving radiological practices globally. Her collaborative efforts have resulted in several joint publications and research initiatives.

PROFESSIONAL DEVELOPMENT

  • Continuous professional development is a cornerstone of Dr. Aydın’s career. She regularly participates in international conferences, workshops, and training programs to stay abreast of the latest advancements in radiology. This commitment to lifelong learning ensures that she remains at the forefront of her field, providing the highest standard of care to her patients.

 

📊🔬Notable Publication:

Extrapulmonary Tuberculosis: An Old but Resurgent Problem

  • Authors: Baykan, A.H., Sayiner, H.S., Aydin, E., Inan, I., Erturk, S.M.
    Journal: Insights into Imaging
  • Year: 2022

 

Quantitative Analysis of the Olfactory System in COVID-19: An MR Imaging Study

  • Authors: Altunisik, E., Baykan, A.H., Sahin, S., Aydin, E., Erturk, S.M.
    Journal: American Journal of Neuroradiology
  • Year: 2021

 

Primary Breast Tuberculosis: Imaging Findings of a Rare Disease

  • Authors: Baykan, A.H., Sayiner, H.S., Inan, I., Aydin, E., Erturk, S.M.
    Journal: Insights into Imaging
  • Year: 2021

 

Reliability of Real-Time Sonoelastography in the Diagnosis of Supraspinatus Tendinopathy

  • Authors: Aydın, E., Söylev, G.Ö., Muratlı, S.K., Tekindal, M.A., Ağıldere, M.
    Journal: Ultrasound Quarterly
  • Year: 2021

 

Optical Coherence Tomography-Angiography Findings of Prediabetic Patients

  • Authors: Emre, S., Altin, C., Ulusoy, M.O., Aydin, E.
    Journal: Oman Journal of Ophthalmology
  • Year: 2024